Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.006
Sell
RSI(14)
33.312
Neutral
STOCH(KDJ)(9,3,3)
15.941
Sell
ATR(14)
0.185
High Vlolatility
CCI(14)
-135.544
Sell
Williams %R
90.000
Oversold
TRIX(12,20)
-1.104
Sell
StochRSI(14)
0.000
Oversold
Precigen Inc
PGEN3.100USD
-0.030-0.96%
Close 03/25, 16:00（ET）Quotes delayed by 15 min
17.55MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Precigen Inc
Currency: USD Updated: 2026-03-25Key Insights
Precigen Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 93 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Precigen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Precigen Inc Highlights
StrengthsRisks
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.36% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.87M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 7.87M.
Fairly Valued
The company’s latest PE is -2.26, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 238.99M shares, increasing 7.80% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 14.54K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 5.55.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
8.500
Target Price
+162.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-25The current financial score of Precigen Inc is 6.18, ranking 145 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 4.62M, representing a year-over-year increase of 288.40%, while its net profit experienced a year-over-year increase of 19.14%.
Score
Financials
4.42
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.96
Operational Efficiency
3.02
Growth Potential
9.14
Shareholder Returns
7.36
Precigen Inc's Company Valuation
Currency: USD Updated: 2026-03-25The current valuation score of Precigen Inc is 6.56, ranking 119 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -2.26, which is -786.16% below the recent high of 15.50 and -416.03% above the recent low of -11.65.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 93/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-25The current earnings forecast score of Precigen Inc is 7.33, ranking 105 out of 157 in the Pharmaceuticals industry. The average price target is 8.50, with a high of 9.00 and a low of 8.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
8.500
Target Price
+162.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Precigen Inc
PGEN
3
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
Gilead Sciences Inc
GILD
32
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-25The current price momentum score of Precigen Inc is 6.63, ranking 106 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 3.69 and the support level at 2.78, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.214
Sell
MA10
3.318
Sell
MA20
3.423
Sell
MA50
4.088
Sell
MA100
4.070
Sell
MA200
3.430
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-25The current institutional shareholding score of Precigen Inc is 5.00, ranking 72 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 67.55%, representing a quarter-over-quarter increase of 7.28%. The largest institutional shareholder is Steven Cohen, holding a total of 18.29M shares, representing 5.17% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Third Security, LLC
Merck Serono SA
Patient Capital Management, LLC
William H. Miller III Living Trust
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Tang Capital Management, LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-03-25The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Precigen Inc is 4.10, ranking 94 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.22. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.22
VaR
+7.83%
240-Day Maximum Drawdown
+40.50%
240-Day Volatility
+94.88%
Return
Best Daily Return
60 days
+8.85%
120 days
+25.65%
5 years
+58.92%
Worst Daily Return
60 days
-9.91%
120 days
-12.99%
5 years
-24.66%
Sharpe Ratio
60 days
-1.33
120 days
+0.23
5 years
+0.22
Risk Assessment
Maximum Drawdown
240 days
+40.50%
3 years
+64.17%
5 years
+90.45%
Return-to-Drawdown Ratio
240 days
+3.04
3 years
+0.81
5 years
-0.12
Skewness
240 days
+3.32
3 years
+2.03
5 years
+1.48
Volatility
Realised Volatility
240 days
+94.88%
5 years
+89.77%
Standardised True Range
240 days
+8.14%
5 years
+5.37%
Downside Risk-Adjusted Return
120 days
+43.71%
240 days
+43.71%
Maximum Daily Upside Volatility
60 days
+51.15%
Maximum Daily Downside Volatility
60 days
+48.38%
Liquidity
Average Turnover Rate
60 days
+2.51%
120 days
+1.62%
5 years
--
Turnover Deviation
20 days
+555.10%
60 days
+190.53%
120 days
+87.33%
Peer Comparison
Pharmaceuticals
Precigen Inc
PGEN
6.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ligand Pharmaceuticals Inc
LGND
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
